Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | HPGD | P15428 | 7/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953445 | 0.79 | GRM5 (0.42) | PLCG1ALDH1A1HPGDCYP11B1SMN1; SMN2 | |
| SCHEMBL24058185 | 0.78 | XDH (0.36) | PLCG1ALDH1A1HPGDCYP11B1SMN1; SMN2 | |
| SCHEMBL7365422 | 0.75 | HPGD (0.40) | PLCG1ALDH1A1HPGDCYP11B1POLB | |
| SCHEMBL3086616 | 0.75 | PLCG1 (0.44) | PLCG1ALDH1A1HPGDCYP11B1SMN1; SMN2 | |
| SCHEMBL10297562 | 0.73 | L3MBTL1 (0.34) | ALDH1A1HPGDNPC1KDM4EMEN1 | |
| SCHEMBL5700318 | 0.72 | ADRA2A (0.33) | ALDH1A1POLBKDM4EL3MBTL1ADRA2A | |
| SCHEMBL5700039 | 0.72 | TRIM24 (0.38) | CYP11B1RAB9APOLBL3MBTL1ADRA2A | |
| SCHEMBL10094206 | 0.72 | HPGD (0.41) | PLCG1ALDH1A1HPGDCYP11B1SMN1; SMN2 | |
| SCHEMBL5700533 | 0.72 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL18485272 | 0.72 | NOS3 (0.47) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-115991703-A | Ring-fused compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4155305-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Guangzhou Fermion Technology Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-113717167-B | Fused ring compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113717167-A | Fused ring compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021233427-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 广州费米子科技有限责任公司 | 2021-11-25 | — | — | WO | disclosed |
| WO-2014010990-A1 | NOVEL PYRIDINE DERIVATIVES AND METHOD FOR PREPARATION OF INTERMEDIATE COMPOUND FOR PRODUCING SULFONYLUREA HERBICIDES USING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2014-01-16 | — | — | WO | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | PLCG1 2967/4885ALDH1A1 2963/4885HPGD 2009/4885 |
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SSTR4, SSTR3, NPY4R | PLCG1 2284/4885ALDH1A1 3727/4885HPGD 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.